RNA - Atrium Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$25.00
DETAILS
HIGH:
$25.00
LOW:
$25.00
MEDIAN:
$25.00
CONSENSUS:
$25.00
UPSIDE:
90.99%
| Metric | 2026 Q1 | 2025 Q4 |
|---|---|---|
| Revenue | ||
| Revenue | 19.6 | 0.9 |
| Cost of Revenue | 0.2 | 0 |
| Gross Profit | 19.5 | 0.9 |
| Operating Expenses | ||
| R&D Expenses | 16.7 | 18.5 |
| SG&A Expenses | 20.1 | 30.4 |
| Other Expenses | 0 | 0 |
| Operating Expenses | 36.8 | 48.9 |
| Operating Income | ||
| Operating Income | (17.3) | (48.0) |
| Interest Expense | 0 | 0 |
| Interest Income | 0 | 0 |
| Profitability | ||
| EBITDA | (17.1) | (47.9) |
| EBIT | (17.3) | (48.0) |
| Income Before Tax | (16.6) | (48.0) |
| Income Tax Expense | 0 | 0.0 |
| Net Income | (16.6) | (48.1) |
| Per Share Data | ||
| EPS (Basic) | -0.97 | -1.70 |
| EPS (Diluted) | -0.97 | -1.70 |
| Shares Outstanding | 17.1 | 17.1 |
| Metric | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 267.8 | 270 | 270 |
| Short-Term Investments | 0 | 0 | 0 |
| Net Receivables | 15 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Other Current Assets | 0.1 | 1.3 | 0 |
| Total Current Assets | 285.6 | 272.8 | 271.3 |
| Non-Current Assets | |||
| Property, Plant & Equipment | 6.4 | 5.5 | 6.3 |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0.4 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 |
| Total Non-Current Assets | 6.8 | 5.5 | 6.3 |
| Total Assets | 292.4 | 278.4 | 277.5 |
| Current Liabilities | |||
| Account Payables | 0.8 | 4.4 | 0.5 |
| Short-Term Debt | 2.7 | 0 | 0 |
| Deferred Revenue | 9.3 | 21.6 | 19.1 |
| Other Current Liabilities | 7.0 | 3.1 | 2.6 |
| Total Current Liabilities | 21.9 | 41.8 | 31.7 |
| Non-Current Liabilities | |||
| Long-Term Debt | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0.6 | 0.6 |
| Total Non-Current Liabilities | 36.4 | 29.3 | 33.0 |
| Total Liabilities | 58.3 | 71.1 | 64.7 |
| Stockholders' Equity | |||
| Common Stock | 0.0 | 0.0 | 0.0 |
| Retained Earnings | 12.1 | 0 | 0 |
| Accumulated Other Comprehensive Income | 0 | 0 | 0 |
| Total Stockholders' Equity | 234.1 | 207.3 | 212.9 |
| Total Liabilities & Equity | 292.4 | 278.4 | 277.5 |
| Debt Metrics | |||
| Total Debt | 2.7 | 3.7 | 4.3 |
| Net Debt | (265.2) | (266.3) | (265.7) |
| Metric | 2026 Q1 | 2025 Q4 |
|---|---|---|
| Operating Activities | ||
| Net Income | (16.6) | (29.1) |
| Depreciation & Amortization | 0.2 | 0.1 |
| Stock-Based Compensation | 0 | 3.6 |
| Change in Working Capital | (27.7) | 5.8 |
| Other Non-Cash Items | 13.1 | 0.4 |
| Operating Cash Flow | (31.1) | (19.3) |
| Investing Activities | ||
| Capital Expenditure | (2.1) | (0.9) |
| Acquisitions | 0 | 0 |
| Purchases of Investments | 0 | 0 |
| Sales/Maturities of Investments | 0 | 0 |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (2.1) | (0.9) |
| Financing Activities | ||
| Net Debt Issuance | 0 | 0 |
| Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 301.5 | 20.1 |
| Financing Cash Flow | 301.5 | 20.1 |
| Cash Position | ||
| Net Change in Cash | 267.8 | 0 |
| Cash at Beginning | 0 | 0 |
| Cash at End | 267.8 | 0 |
| Free Cash Flow | (33.2) | (20.1) |
| Key Metrics | 2026 Q1 | 2025 Q4 | |
|---|---|---|---|
| Income Statement | |||
| Revenue | 19.6 | 0.9 | |
| Gross Profit | 19.5 | 0.9 | |
| Operating Income | (17.3) | (48.0) | |
| Net Income | (16.6) | (48.1) | |
| EPS (Diluted) | -0.97 | -1.70 | |
| Balance Sheet | |||
| Cash & Equivalents | 267.8 | 270 | 270 |
| Total Assets | 292.4 | 278.4 | 277.5 |
| Total Debt | 2.7 | 3.7 | 4.3 |
| Stockholders' Equity | 234.1 | 207.3 | 212.9 |
| Cash Flow | |||
| Operating Cash Flow | (31.1) | (19.3) | |
| Capital Expenditure | (2.1) | (0.9) | |
| Free Cash Flow | (33.2) | (20.1) | |